Dr. Doherty’s initial research identified novel therapeutic targets for the airway inflammation and remodeling that occur in chronic asthma pathology. The Doherty lab has since developed a focus on innate type 2 lung responses that contribute to asthma and allergic airway disease. We have identified novel mechanisms that regulate group 2 innate lymphoid cells (ILC2s) using animal models and human samples.
Funding for the Doherty lab has been provided by: The National Institute of Allergy and Infectious Disease (NIAID), the American Lung Association (ALA), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and UCSD CTRI.